NFE2 and myeloproliferative neoplasm: JMJD1C participates in an auto-regulatory loop, as it is both a target of the transcription factor NFE2, overexpressed in the large majority of MPN patients, and also binds the NFE2 promoter, thereby enhancing NFE2 expression.